+

DK0811384T3 - Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof - Google Patents

Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof

Info

Publication number
DK0811384T3
DK0811384T3 DK96901998T DK96901998T DK0811384T3 DK 0811384 T3 DK0811384 T3 DK 0811384T3 DK 96901998 T DK96901998 T DK 96901998T DK 96901998 T DK96901998 T DK 96901998T DK 0811384 T3 DK0811384 T3 DK 0811384T3
Authority
DK
Denmark
Prior art keywords
muscle protein
antibodies
antibody
receptor antibody
protein degradation
Prior art date
Application number
DK96901998T
Other languages
Danish (da)
English (en)
Inventor
Toshimasa Tsujinaka
Chikara Ebisui
Junya Fujita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0811384T3 publication Critical patent/DK0811384T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK96901998T 1995-02-13 1996-02-13 Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof DK0811384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4658795 1995-02-13
JP33435695 1995-11-30

Publications (1)

Publication Number Publication Date
DK0811384T3 true DK0811384T3 (da) 2006-10-09

Family

ID=26386686

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96901998T DK0811384T3 (da) 1995-02-13 1996-02-13 Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof

Country Status (11)

Country Link
US (1) US6261560B1 (fr)
EP (1) EP0811384B1 (fr)
JP (1) JP4540132B2 (fr)
AT (1) ATE330629T1 (fr)
AU (1) AU693318B2 (fr)
CA (1) CA2211578C (fr)
DE (1) DE69636278T2 (fr)
DK (1) DK0811384T3 (fr)
ES (1) ES2264135T3 (fr)
PT (1) PT811384E (fr)
WO (1) WO1996025174A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298790B6 (cs) * 1994-10-21 2008-01-30 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení kachexie
CA2284271C (fr) 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE69839517D1 (de) * 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
EP1074268B1 (fr) * 1998-03-17 2008-01-16 Chugai Seiyaku Kabushiki Kaisha Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant des anticorps antagonistes du recepteur a l' il-6
US6982325B1 (en) 1998-04-17 2006-01-03 Suntory Flowers Limited Gene encoding protein having aurone synthesizing activity
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
EP1347300B1 (fr) * 2000-11-30 2007-04-18 Chugai Seiyaku Kabushiki Kaisha Procede de mesure de l'activite de liaison d'une proteine se liant a un ligand presentant une faible stabilite chimique a un premier ligand
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP2007528691A (ja) * 2001-11-14 2007-10-18 セントカー・インコーポレーテツド 抗ｉｌ−６抗体、組成物、方法および使用
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
JP4555924B2 (ja) * 2003-02-24 2010-10-06 中外製薬株式会社 インターロイキン−６アンタゴニストを含有する脊髄損傷治療剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2007043641A1 (fr) 2005-10-14 2007-04-19 Fukuoka University Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
WO2007046489A1 (fr) * 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique pour maladie de coeur
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
CN101495146B (zh) * 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2057191A1 (fr) 2006-08-18 2009-05-13 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
TWI561530B (en) * 2007-05-21 2016-12-11 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2728243C (fr) 2008-06-05 2020-03-10 National Cancer Center Inhibiteur de neuro-invasion
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
WO2010115995A2 (fr) 2009-04-10 2010-10-14 Ablynx Nv Séquences d'acides aminés améliorées dirigées contre l'il-6r et polypeptides les comprenant pour le traitement des maladies et des troubles liés à l'il-6r
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
EP2638067A2 (fr) 2010-11-08 2013-09-18 Genentech, Inc. Anticorps anti-récepteur de l'il-6 administré par voie sous-cutanée
WO2012071561A2 (fr) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anticorps anti-il-6 pour le traitement de l'anémie
SG192118A1 (en) 2011-01-28 2013-09-30 Sanofi Sa Pharmaceutical compositions comprising human antibodies to pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
DK2747782T3 (en) * 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2015000865A1 (fr) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Dosage immunologique à interférence supprimé et pour détecter des anticorps anti-médicament dans des échantillons de sérum
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患の処置
MA42657A (fr) 2015-08-18 2018-06-27 Regeneron Pharma Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
EP3596175A4 (fr) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation Nanoparticules pour l'administration d'agents chimiopréventifs
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP7065589B2 (ja) * 2017-10-31 2022-05-12 株式会社明治 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
US12297279B2 (en) 2019-06-04 2025-05-13 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187645A (ja) * 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
IL101692A0 (en) 1991-05-03 1992-12-30 Amgen Inc Recombinant b oligomer of pertussis toxin
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
WO1994008574A1 (fr) * 1992-10-13 1994-04-28 Otsuka America Pharmaceutical, Inc. Traitement de la cachexie et inhibition de l'activite de il-6

Also Published As

Publication number Publication date
ATE330629T1 (de) 2006-07-15
DE69636278D1 (de) 2006-08-03
DE69636278T2 (de) 2007-05-03
EP0811384A1 (fr) 1997-12-10
AU4634296A (en) 1996-09-04
JP4540132B2 (ja) 2010-09-08
WO1996025174A1 (fr) 1996-08-22
ES2264135T3 (es) 2006-12-16
AU693318B2 (en) 1998-06-25
CA2211578C (fr) 2010-09-21
PT811384E (pt) 2006-11-30
EP0811384B1 (fr) 2006-06-21
US6261560B1 (en) 2001-07-17
EP0811384A4 (fr) 2002-09-18
CA2211578A1 (fr) 1996-08-22

Similar Documents

Publication Publication Date Title
DK0811384T3 (da) Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
NZ513699A (en) Recombinant IL-18 antagonists useful in treatment of IL-18 mediated disorders
IL103981A0 (en) Pharmaceutical compositions for treatment of multiple sclerosis
ATE407696T1 (de) Vorbeugende- oder heilmittel zur behandlung von multipler sklerose, mit antagonistischen anti-il6-rezeptor antikörpern als wirkstoff
EA199700265A1 (ru) Добавочный протеин рецептора интерлейкина-1 человека
WO1997017446A3 (fr) ANTICORPS HUMANISES DIRIGES CONTRE LA gp39 D'ORIGINE HUMAINE, COMPOSITIONS CONTENANT CES ANTICORPS ET LEUR UTILISATION THERAPEUTIQUE
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
ATE454141T1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
DE69939316D1 (de) Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
PT839196E (pt) Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
DK1265928T3 (da) RSV-neutraliserende antistoffer med ultra høj affinitet
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
MY125875A (en) Method and food product for increasing muscle protein and reducing fat in animals
NO940809D0 (no) Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist
DK132284D0 (da) Immunoglobulin-g-holdig fraktion
EP1137766A4 (fr) Modele animal du psoriasis destine a la prevention et au traitement du psoriasis humain
NO944931D0 (no) Anvendelse av 2-fenyl-3-arroylbenzotiofener for inhibering av tidlig seksuell modenhet
DE69626522D1 (de) Peptide mit pronociceptiveigenschaften
ATE149089T1 (de) Anwendungsgebiete von beta-adrenergenen agonisten
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
CA2308007A1 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
MY118946A (en) Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides
WO2001072334A3 (fr) Procedes de traitement de maladie avec des anticorps diriges contre cxcr3
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载